Reslizumab: Effectiveness one month after first dose

Introduction: Reslizumab is a humanized monoclonal antibody against Interleukin-5 which is administered every 4 weeks intravenously in patients with severe eosinophilic asthma. Aims and Objetives: Analyze changes in lung function and asthma symptoms. We perform measures before starting the treatment and 28 days later. Methods: We registered prospectively patient characteristics , FEV1 , and asthma control using Asthma control test (ACT) . We record this data before starting treatment and 28 days later. Results: We registered 11 patients ( 11 female ). Mean age 58,09 ± 12,5 years. Two patients (18,2 %) had received Mepolizumab before starting Reslizumab. Two patients had received (18,2%) Omalizumab before starting Reslizumab. Previous treatments were suspended due to clinical failure. Lung function: Mean FEV1 pre-treatment was 2014,23 ml ; mean FEV1 post-treatment was 2286,23 ml. Mean improvement in FEV-1% of pre-treatment value was 13,05%, 272 ml. (p ACT score improves 4,64. Mean ACT score improved from 16,45 after treatment to 21,19 after 1 month of treatment. (p One patient had ACT ≥ 20 before treatment. After treatment, 8 patients had ACT score ≥ 20. We didn´t observe exacerbations during this period. No side-effects were observed. Conclusion: Our data suggest that Reslizumab improves lung fuction and asthma control in patients with eosinophilic severe asthma after the first dose.